• Bausch + Lomb recently faced a Portnoy Law Firm investigation into possible securities fraud after disclosing a voluntary recall of its enVista intraocular lenses linked to increased reports of toxic anterior segment syndrome, which the company said would create headwinds for revenue and adjusted EBITDA.
• At the same time, CEO and Chairman Brenton L. Saunders’ presentation at the Longwood Healthcare Leaders Miami conference offered investors a forum to gauge how management addresses the recall, legal scrutiny and their potential impact on the broader eye health portfolio.
• We’ll now consider how the enVista intraocular lens recall and related legal investigation could influence Bausch + Lomb’s previously outlined investment narrative.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Bausch + Lomb Investment Narrative Recap

Bausch + Lomb’s investment case centers on broad exposure to eye health across pharmaceuticals, vision care and surgical devices, with improving profitability as a key near term catalyst. The enVista intraocular lens recall and Portnoy Law Firm investigation directly touch the Surgical segment and could complicate that margin story, while also elevating legal and reputational risk as the most immediate overhang for the business.

In that context, CEO Brenton Saunders’ appearance at the Longwood Healthcare Leaders Miami conference takes on added importance, giving investors a timely opportunity to hear how management frames the recall, addresses legal scrutiny and situates these issues against previously issued 2026 revenue guidance of US$5.375 billion to US$5.475 billion and expected constant currency growth of 5% to 7%.

Yet behind the headline recall and investigation, one important risk that investors should be aware of is...

Bausch + Lomb's narrative projects $5.9 billion revenue and $252.2 million earnings by 2028. This requires 5.7% yearly revenue growth and a $557.2 million earnings increase from $-305.0 million today.

Uncover how Bausch + Lomb's forecasts yield a $17.25 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Before this recall, the most pessimistic analysts still expected revenue to reach about US$5.8 billion and earnings of roughly US$247 million, yet they worried that any setback in premium intraocular lenses after enVista could undermine that recovery path, reminding you that views on BLCO’s risks and potential can differ sharply and may shift again as this story develops.

Explore 4 other fair value estimates on Bausch + Lomb - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.